Can Vitamin E Cause Cancer? What the Evidence Shows

High-dose vitamin E supplements can increase the risk of certain cancers, most convincingly prostate cancer in men. The strongest evidence comes from a large randomized trial of more than 35,000 men, which found that daily supplementation with 400 IU of synthetic alpha-tocopherol raised prostate cancer risk by about 17 percent compared to placebo. That finding surprised many researchers, because vitamin E had long been considered a promising cancer-prevention agent based on its antioxidant properties. The story turns out to be far more complicated than “antioxidant good, free radical bad,” and the answer depends heavily on the dose, the form of vitamin E, whether you already have cancer, and even your genetic makeup.

The Trial That Changed the Conversation

For decades, the hypothesis was straightforward: free radicals damage DNA, antioxidants neutralize free radicals, so antioxidants should prevent cancer. Laboratory and animal studies supported this logic, showing that antioxidants could prevent the kind of cellular damage linked to tumor development.¹ Then the clinical trials in humans started reporting back, and the results did not cooperate.

The Selenium and Vitamin E Cancer Prevention Trial, known as SELECT, enrolled over 35,000 men across the United States, Canada, and Puerto Rico to test whether vitamin E, selenium, or both could prevent prostate cancer. The initial results published in 2008 showed a non-significant trend toward more prostate cancer cases in the vitamin E group, with a hazard ratio of 1.13, but the confidence interval crossed 1.0, meaning the increase could have been due to chance.² The trial was stopped early because of this worrying signal and clear lack of benefit.

With additional follow-up through 2011, that trend solidified. Men who had taken vitamin E alone developed prostate cancer at a significantly higher rate: 620 cases versus 529 in the placebo group, for a hazard ratio of 1.17. That translates to roughly 1.6 extra prostate cancer cases per 1,000 men per year of supplementation.³ The increase persisted even after men stopped taking the supplements, suggesting the effect was not immediately reversible.

Earlier Trials Told a Muddled Story

Before SELECT, the largest evidence came from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, known as ATBC, which ran in the 1990s among Finnish male smokers. That trial found the opposite result for prostate cancer: fewer cases among men receiving alpha-tocopherol than among those who did not.⁴ The ATBC trial also found fewer colorectal cancer cases in the vitamin E group but more stomach cancers, so the results were mixed even within a single trial.⁵

The ATBC findings were partly what motivated SELECT in the first place. Researchers hoped to confirm the prostate cancer reduction in a larger, more diverse population. Instead, they found the opposite. The discrepancy is likely explained by differences in the study populations (ATBC enrolled only heavy smokers, while SELECT enrolled generally healthy men), different doses, and the fact that SELECT used a synthetic form of alpha-tocopherol rather than the natural form used in ATBC. It also highlights how a promising signal in one population can collapse or even reverse in another.

Why an Antioxidant Might Help Tumors Grow

The idea that an antioxidant could promote cancer seems contradictory until you consider what antioxidants actually do inside a cell that is already becoming cancerous. Healthy cells benefit when free radicals are kept in check, because free radical damage to DNA can trigger mutations. But cells that have already acquired early mutations face a different situation. The body’s own defenses, particularly a tumor-suppressor protein called p53, use oxidative stress as a signal to slow down or kill damaged cells. When an antioxidant swoops in and lowers that oxidative stress, it can effectively remove one of the body’s brakes on early tumor growth.

A 2014 study in mice demonstrated this directly. Vitamin E and another antioxidant called NAC accelerated lung tumor growth by reducing oxidative damage and suppressing p53 activity in tumor cells. The effect was on existing early tumors and precancerous lesions, not on healthy tissue.⁶ The implication is stark: if you already have small, undetected tumors or precancerous patches, flooding your body with supplemental antioxidants might give those abnormal cells a survival advantage.

More recent research has extended this to metastasis, the process by which cancer cells spread from one organ to another. Cancer cells trying to colonize distant tissues face intense oxidative stress in the bloodstream and in unfamiliar tissue environments. That stress kills most of them. But antioxidants, including vitamin E analogs, can reduce that stress and help more cancer cells survive the journey. In mouse models of melanoma, a vitamin E analog increased cancer cell migration and invasion.⁷ This does not mean vitamin E causes metastasis in humans, but it illustrates how the “antioxidants are always protective” narrative falls apart once cancer cells are already present.

At high doses, vitamin E can also behave as a pro-oxidant under certain conditions, which is the opposite of what most people expect. In one study of cigarette smokers eating a diet high in polyunsaturated fats, adding vitamin E actually increased markers of oxidative damage rather than decreasing them.⁸ At supplemental doses, the balance between antioxidant benefit and interference with normal cellular processes can tip in the wrong direction, disrupting immunity, cell growth signaling, and the body’s natural oxidative-stress management.⁹

Not All Vitamin E Is the Same

This is where the story gets genuinely interesting and genuinely frustrating. When people say “vitamin E,” they almost always mean alpha-tocopherol, which is the form used in most supplements and the form the body preferentially retains. But vitamin E is actually a family of eight related molecules: four tocopherols and four tocotrienols. The clinical trials that raised cancer concerns used alpha-tocopherol exclusively. Other members of the family may behave very differently.

Gamma-tocopherol, the form most abundant in the American diet through soybean and corn oils, and delta-tocopherol, a less common form, have shown stronger anti-cancer activity than alpha-tocopherol in laboratory and animal experiments. In animal models of lung tumors, delta-tocopherol significantly reduced tumor volume and weight, increased cancer-cell death, and reduced markers of DNA damage, while alpha-tocopherol had no significant effect on any of those measures.¹⁰ A mixture rich in gamma-tocopherol inhibited tumor development in animal models of colon, prostate, breast, and lung cancer.¹¹

Here is the kicker: high-dose alpha-tocopherol supplements actually lower your blood and tissue levels of gamma- and delta-tocopherol. So taking a large alpha-tocopherol supplement might simultaneously provide a form with weak anti-cancer activity while depleting the forms that appear to be more protective.¹¹ This displacement effect is one plausible explanation for why supplementation trials have not matched the cancer-prevention hopes that observational studies had raised.

It is worth noting that this research is largely in animals and cell cultures. No large human trials have tested gamma- or delta-tocopherol for cancer prevention. The evidence is suggestive enough to explain why alpha-tocopherol trials failed, but not enough to recommend switching to a different tocopherol supplement.

Food Sources Versus Pills

Researchers who have examined the full body of evidence have drawn a useful distinction: at nutritional levels, all forms of vitamin E appear to be cancer-preventive, which is consistent with many observational studies linking higher dietary vitamin E intake and higher blood levels of tocopherols with lower cancer risk. At supranutritional levels delivered by supplements, alpha-tocopherol has not been cancer-preventive and may increase risk.¹²

The likely explanation ties back to the isoform issue. When you eat nuts, seeds, vegetable oils, and leafy greens, you get a natural mix of alpha-, gamma-, and delta-tocopherol, along with tocotrienols. The amounts are modest, perhaps 15 to 20 milligrams of total vitamin E per day in a typical diet. A standard supplement delivers 180 to 400 milligrams of alpha-tocopherol alone, more than ten times what you would get from food and exclusively in the one form that appears least protective against cancer. The supplement overwhelms the system, displaces the other tocopherols, and may tip normal cell-signaling processes off balance.

For most people who eat a reasonably varied diet, vitamin E deficiency is extremely rare. The people most likely to be deficient are those with fat-malabsorption conditions, because vitamin E is fat-soluble and absorbed along with dietary fat. If you do not have such a condition, food alone almost certainly provides enough vitamin E to support its normal biological roles without venturing into the territory where risk signals emerge.

The Mortality Question

Beyond cancer specifically, there is a broader concern about high-dose vitamin E and dying from any cause. A meta-analysis that pooled data from 19 clinical trials found that high-dose vitamin E supplementation, at 400 IU per day or more, was associated with about 39 extra deaths per 10,000 people compared to placebo. A dose-response analysis found increased mortality risk beginning at doses above 150 IU per day.¹³ Low-dose trials did not show this increase. The causes of death were varied and not attributable to cancer alone; possible contributing mechanisms include interference with blood clotting, increased hemorrhagic stroke risk, and the pro-oxidant effects described above.

This finding was controversial when published and has been debated since, but no subsequent large trial has refuted it. If anything, the SELECT prostate cancer results added further evidence that high-dose supplementation carries real downside risk.

Genetics May Shift the Balance

Your individual response to vitamin E may depend partly on your genes. In a study of Korean adults, the relationship between dietary vitamin E and colorectal cancer risk depended on a specific genetic variant in the COMT gene. People with at least one copy of a particular version of that gene showed a significant protective association between higher vitamin E intake and lower colorectal cancer risk, while those without it did not.¹⁴ In a separate analysis, genetic variants that are associated with naturally higher circulating vitamin E levels were linked to reduced prostate cancer risk, with one variant associated with roughly a 25 percent reduction.¹⁵

This presents a paradox: genetic markers that predict higher natural vitamin E status are associated with lower cancer risk, yet supplementing with large doses of alpha-tocopherol raises risk. The resolution probably lies in the difference between modestly higher levels of a natural mix of tocopherols, which is what those genetic variants reflect, versus massively elevated levels of a single synthetic form. Your genes influence how you absorb, transport, and metabolize vitamin E, which means the same supplement dose could have different effects in different people. No genetic test currently available can tell you whether vitamin E supplementation is safe or risky for you specifically, but this research helps explain why population-level trials produce messy results.

The Supplement Industry and the Messaging Gap

Despite the evidence from SELECT and the mortality meta-analysis, vitamin E supplements remain widely sold, and marketing language continues to imply anti-cancer benefits. This is not a fringe problem. Supplement use is driven in part by the belief that nutritional supplements can ward off chronic diseases including cancer, even though multiple expert committees have concluded there is little to no scientific evidence supporting that claim. In fact, the evidence now points in the opposite direction for high-dose vitamin E specifically.¹⁶

Part of the disconnect is regulatory. In the United States, dietary supplements do not need to prove efficacy or safety before going to market in the way that drugs do. A manufacturer can sell 400 IU vitamin E capsules and describe the product as an “antioxidant” without mentioning the SELECT findings. Consumers who remember the early excitement about antioxidants from the 1990s may have never encountered the clinical trial results that came later.

What the Official Limits Look Like

The European Food Safety Authority set its tolerable upper intake level for vitamin E at 300 milligrams per day for adults, which is equivalent to roughly 450 IU of natural alpha-tocopherol. That level was based on the risk of bleeding complications rather than cancer risk specifically, since the cancer data emerged after the original limit was set.¹⁷ The authority also noted that these limits do not apply to people taking anticoagulant medications, who face additional bleeding risks from vitamin E. In the United States, the National Institutes of Health sets the tolerable upper intake for adults at 1,000 milligrams per day of any form of supplemental alpha-tocopherol, a much more permissive ceiling.

Even at doses below these formal upper limits, the mortality meta-analysis found increased risk starting around 150 IU per day, well within what many supplement labels suggest.¹³ The gap between the official ceiling and the dose at which risk signals appear makes it easy for consumers to assume they are safe at doses that may not be.

If You Already Have Cancer

The question takes on a different character for people already diagnosed with cancer or undergoing treatment. The animal and cell-culture data on antioxidants helping cancer cells survive oxidative stress is concerning enough that most oncologists advise against high-dose antioxidant supplements during chemotherapy or radiation, both of which work partly by generating oxidative stress inside tumor cells. Taking an antioxidant supplement during treatment could, in theory, protect the very cells the treatment is trying to destroy.

A systematic review examining the safety of vitamin C, vitamin E, and selenium in the oncology setting found limited high-quality evidence to support or refute supplement use alongside cancer treatment.¹⁸ The absence of evidence is not reassurance; it means the question has not been answered rigorously enough to make confident recommendations. Given the mechanistic concern that antioxidants could shield tumor cells from treatment, the conservative approach during active cancer therapy is to avoid supplementation unless directed by your oncology team.

Why Smokers Deserve a Separate Warning

Smokers occupy a unique risk category in this discussion. Cigarette smoke generates enormous oxidative stress, which is why smokers were among the first populations studied for potential antioxidant benefit. The ATBC trial enrolled exclusively heavy smokers, and it was in that group that alpha-tocopherol initially appeared to reduce prostate cancer risk.⁴ But the ATBC trial also found that beta-carotene, another antioxidant, increased lung cancer risk in smokers, and the mouse research on antioxidants accelerating early lung tumors is particularly relevant for people whose lungs already carry smoke-related precancerous changes.⁶

On top of that, vitamin E can behave as a pro-oxidant in smokers eating high-fat diets, increasing rather than decreasing markers of oxidative damage.⁸ The combination of potentially feeding early lung lesions and paradoxically increasing oxidative stress makes high-dose vitamin E supplementation a particularly poor bet for current smokers. If you smoke, putting down the cigarettes will do more for your cancer risk than any supplement could, and adding vitamin E on top might make things worse.

1
National Cancer Institute. Antioxidants and Cancer Prevention
2
PubMed Central. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
3
PubMed Central. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
4
PubMed. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
5
The American Journal of Clinical Nutrition. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study
6
PubMed. Antioxidants accelerate lung cancer progression in mice
7
PubMed Central. Effects of antioxidants on cancer progression
8
PubMed. Pro-oxidant effect of vitamin E in cigarette smokers consuming a high polyunsaturated fat diet
9
PubMed Central. Vitamin E (α-Tocopherol): Emerging Clinical Role and Adverse Risks of Supplementation in Adults
10
PubMed Central. δ-Tocopherol Is More Active than α- or γ-Tocopherol in Inhibiting Lung Tumorigenesis In Vivo
11
Carcinogenesis. Cancer-preventive activities of tocopherols and tocotrienols
12
PubMed Central. Does Vitamin E Prevent or Promote Cancer?
13
PubMed. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality
14
PubMed Central. Interaction between vitamin E intake and a COMT gene variant on colorectal cancer risk among Korean adults: a case-control study
15
The Journal of Nutrition. Genetic Variants Reflecting Higher Vitamin E Status in Men Are Associated with Reduced Risk of Prostate Cancer
16
PubMed Central. Dietary supplements and cancer prevention: balancing potential benefits against proven harms
17
PubMed Central. Scientific opinion on the tolerable upper intake level for vitamin E
18
PubMed. Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review